Zynerba Pharmaceuticals Inc. (ZYNE) Trading Down 0.8%
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) shares fell 0.8% during trading on Friday . The stock traded as low as $7.16 and last traded at $7.36, with a volume of 101,558 shares. The stock had previously closed at $7.30.
Several research firms recently commented on ZYNE. Jefferies Group reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, April 7th. Roth Capital began coverage on shares of Zynerba Pharmaceuticals in a report on Thursday, March 17th. They issued a “buy” rating and a $25.00 price objective for the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, April 18th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Zynerba Pharmaceuticals in a report on Wednesday, March 16th. Finally, Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.60.
The stock has a 50 day moving average of $7.90 and a 200-day moving average of $8.31. The stock’s market cap is $67.70 million.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Thursday, May 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.07. On average, equities analysts anticipate that Zynerba Pharmaceuticals Inc. will post ($2.37) earnings per share for the current fiscal year.
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.